Skip to content

Study · Observational study · n = 113 · 2024

5 results

Short-term effects of semaglutide among patients with obesity with and without food addiction: an observational study.

Nicolau J, Tamayo MI, Sanchís P, Pujol A, Pérez-Bec G, Sfondrini G, Masmiquel L

Journal of addictive diseases18 Feb 2024Cited by 13 (Europe PMC)

PMID38369467 (opens in a new tab)DOI10.1080/10550887.2024.2315365 (opens in a new tab)PepBankPUB-38369467
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with obesity, the prevalence of food addiction fell from 57.5% to 4.2% after four months of semaglutide.

    In plain wordsIn adults with obesity, fewer people showed food addiction after four months of semaglutide treatment.

    Peptide
    Semaglutide
    Outcome
    DecreasePrevalence of food addiction
    Study

    n = 113

    Outcome group
    Appetite and food intake · Mental health and mood
    Studied dose
    Dose not stated · 4 monthsAs given in this study (human).

    Measurements

    Food addiction prevalence
    57.5%
    before treatment
    Food addiction prevalence
    4.2%
    after 4 months

    Source sentences

    Summary
    After four months of treatment with semaglutide, the prevalence of FA diminished from 57.5% to 4.2% (p < .001).
    1 context sentence
    Summary · context
    One hundred and thirteen PwO (45.5 ± 10.2 years) were evaluated anthropometrically baseline and after four months of treatment with semaglutide.
  2. 02HumanObservational studyEfficacy outcome

    In adults with obesity treated with semaglutide, percentage weight loss was comparable between patients with and without food addiction.

    In plain wordsIn adults with obesity on semaglutide, weight loss was similar in people with and without food addiction.

    Peptide
    Semaglutide
    Outcome
    No significant changePercentage weight loss, with versus without food addiction
    Study

    n = 113

    Comparator
    Patients without food addiction
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 4 monthsAs given in this study (human).

    Measurements

    Weight loss
    6.9%
    with food addiction
    Weight loss
    5.3%
    without food addiction

    Source sentences

    Summary
    The percentage of weight loss (6.9 ± 12.7 vs 5.3 ± 4.6%; p = .4) and the proportion of fat mass loss (2 ± 9 vs 1.6 ± 3.1%; p = .7) were comparable between PwO with and without FA.
    1 context sentence
    Summary · context
    One hundred and thirteen PwO (45.5 ± 10.2 years) were evaluated anthropometrically baseline and after four months of treatment with semaglutide.
  3. 03HumanObservational studyEfficacy outcome

    In adults with obesity treated with semaglutide, the proportion of fat mass loss was comparable between patients with and without food addiction.

    In plain wordsIn adults with obesity on semaglutide, fat mass loss was similar in people with and without food addiction.

    Peptide
    Semaglutide
    Outcome
    No significant changeFat mass loss, with versus without food addiction
    Study

    n = 113

    Comparator
    Patients without food addiction
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 4 monthsAs given in this study (human).

    Measurements

    Fat mass loss
    2%
    with food addiction
    Fat mass loss
    1.6%
    without food addiction

    Source sentences

    Summary
    The percentage of weight loss (6.9 ± 12.7 vs 5.3 ± 4.6%; p = .4) and the proportion of fat mass loss (2 ± 9 vs 1.6 ± 3.1%; p = .7) were comparable between PwO with and without FA.
    1 context sentence
    Summary · context
    One hundred and thirteen PwO (45.5 ± 10.2 years) were evaluated anthropometrically baseline and after four months of treatment with semaglutide.
  4. 04HumanObservational studySafety outcome

    In adults with obesity treated with semaglutide, side effects did not differ between patients with and without food addiction.

    In plain wordsIn adults with obesity on semaglutide, side effects were similar in people with and without food addiction.

    Peptide
    Semaglutide
    Outcome
    No significant changeSide effects, with versus without food addiction
    Study

    n = 113

    Comparator
    Patients without food addiction
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    No differences regarding side effects and treatment discontinuations were seen between the two groups.
    1 context sentence
    Summary · context
    One hundred and thirteen PwO (45.5 ± 10.2 years) were evaluated anthropometrically baseline and after four months of treatment with semaglutide.
  5. 05HumanObservational studySafety outcome

    In adults with obesity treated with semaglutide, treatment discontinuations did not differ between patients with and without food addiction.

    In plain wordsIn adults with obesity on semaglutide, stopping treatment was equally common in people with and without food addiction.

    Peptide
    Semaglutide
    Outcome
    No significant changeTreatment discontinuations, with versus without food addiction
    Study

    n = 113

    Comparator
    Patients without food addiction
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    No differences regarding side effects and treatment discontinuations were seen between the two groups.
    1 context sentence
    Summary · context
    One hundred and thirteen PwO (45.5 ± 10.2 years) were evaluated anthropometrically baseline and after four months of treatment with semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.